Page 41 - GALENIKA MEDICAL JOURNAL
P. 41
45. Rider DA, Eisermann M, Löffler K, Aleku M, Swerdlow DI, Dames S, et 51. Lee RG, Mazzola AM, Braun MC, Platt C, Vafai SB, Kathiresan S, et al.
al. Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, Efficacy and Safety of an Investigational Single-Course CRISPR Base-
developed to address elevated lipoprotein (a) in cardiovascular disease. Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse
Atherosclerosis. 2022 May;349:240-7. Models. Circulation. 2023 Jan 17;147(3):242-53.
46. Chambergo-Michilot D, Alur A, Kulkarni S, Agarwala A. Mipomersen in 52. Vafai SB, Gladding PA, Scott R, Kerr J, Taube J, Cegla J, et al. Safety and
Familial Hypercholesterolemia: An Update on Health-Related Quality of Pharmacodynamic Effects of VERVE-101; An Investigational DNA Base
Life and Patient-Reported Outcomes. Vasc Health Risk Manag. 2022 Feb Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and
21;18:73-80. Lower LDL Cholesterol – Interim Results of the Phase 1b heart-1 Trial:
Available online: https://www.vervetx.com/sites/default/files/2023-11/
47. D'Erasmo L, Steward K, Cefalù AB, Di Costanzo A, Boersma E, Bini Verve
S, et al. Italian and European Working Group on Lomitapide in
HoFH. Efficacy and safety of lomitapide in homozygous familial
hypercholesterolaemia: the pan-European retrospective observational Konflikt interesa: Nema
study. Eur J Prev Cardiol. 2022 May 5;29(5):832-41.
48. Raal F, Fourie N, Scott R, Blom D, De Vries Basson M, Kayikcioglu M, Primljeno: 26. 01. 2024.
et al. LIBerate-HeFH Investigators. Long-term efficacy and safety of Prihvaćeno: 19. 02. 2024.
lerodalcibep in heterozygous familial hypercholesterolaemia: the
LIBerate-HeFH trial. Eur Heart J. 2023 Oct 21;44(40):4272-80. Onlajn: 31. 03. 2024.
49. Ballantyne CM, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A,
et al. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J
Am Coll Cardiol. 2023 Apr 25;81(16):1553-64.
50. Fowler A, Van Rompay KKA, Sampson M, Leo J, Watanabe JK, Usachenko
JL, et al. A virus-like particle-based bivalent PCSK9 vaccine lowers
LDL-cholesterol levels in non-human primates. NPJ Vaccines. 2023 Sep
28;8(1):142.
REVIJALNI RADOVI Galenika Medical Journal, 2024; 3(9):31-39. 39
